Jefferies reiterates AC Immune stock Buy rating on vaccine data By Investing.com

Jefferies reiterated a Buy and $7 price target on AC Immune (current $3.15), implying >120% upside; the stock is +7.5% over the past week and +30% over the past year. Key catalysts: 1H-2026 PET clearance data for ACI-24 (35% of NPV) and a Q3-2026 Phase II readout for ACI-7104 (20% of NPV); FDA clarity could reduce the valuation gap. AC Immune has initiated Phase 1 dosing of oral ACI-19764 (NLRP3 inhibitor), and the firm says cash runway extends into Q3-2027, though the company is burning cash and a Phase II recruitment pause for ACI-35 remains unresolved.

Analysis

The market is treating this company as a classic binary clinical story where one mid‑stage biomarker readout and a partner opt‑in decision account for most of the upside; small changes in perceived success probability (10–20 percentage points) would plausibly move the equity by multiples, creating asymmetric outcomes for near‑term directional trades. Because the company also runs a small‑molecule inflammasome program, positive clinical signals would simultaneously validate two distinct commercialization paths — raising strategic optionality (partnering vs internal development) and making a takeover by a major pharma materially more likely.

A successful readout would have second‑order supply effects: contract manufacturers with peptide/oligo capabilities and radiochemistry/PET service providers would see a sudden pick‑up in demand, tightening capacity and driving margin tailwinds for selected CMOs; conversely, a negative outcome would not just hit the equity but could chill appetite for other active‑immunotherapy programs, amplifying downside across a narrow group of small neuro‑biotechs. The balancing factor is cash runway dynamics — unless a partner exercises a deal option or the company secures non‑dilutive funding, board choices in the next 12–18 months (dilution vs strategic transaction) are the key macro lever on equity dilution risk.

Regulatory clarity from authorities on acceptable endpoints and PET‑based surrogates is the wildcard that can compress valuation dispersion; explicit FDA guidance would convert binary speculation into a more tradable, probability‑weighted story. Near‑term tradeability is highest around data and partner decision windows; absent those catalysts, volatility should mean-revert lower and the premium in options decays rapidly, favoring directional outright or spreaded structures rather than unhedged loans of stock.

Key Decisions for Investors

• Event‑driven long (ACI U): Buy a 12–18 month call spread on ACIU to limit downside while keeping upside to a positive readout (example structure: buy 1 LEAP call, sell 1 higher strike call ~1.5–2x strike). Position size 2–4% portfolio; target 3x+ on premium if readout validates biomarker and partner interest; cut to 40–50% if pre‑readout leak undermines probability.
• Hedge and insurance (ACI U): If already long equity, buy near‑term OTM protective puts (30–60 day) sized at ~25–40% of position to protect against a negative binary; cost should be treated as insurance — accept ~10–15% drag for crash protection given asymmetric downside.
• Pair trade to isolate asset risk: Go long ACIU (equity or calls) and short a small‑cap biotech ETF (XBI) equal‑dollar to isolate program‑specific upside vs sector beta. Expect this to outperform if company‑specific data is positive while general risk‑off persists; unwind if sector flows reverse strongly.
• Supply‑chain long: Buy select CMOs with peptide/oligo and PET radiochemistry exposure (e.g., Catalent CTLT or Lonza LZAGY) as a low‑beta way to capture upside if the modality is validated. Size 0.5–1.5% each; these are slower plays — 6–24 month horizon with lower volatility than the sponsor equity.